Glenmark Pharmaceuticals, a drug firm said it has received final approval for Abiraterone Acetate tablets from the US health regulator. These tablets are used in treatment of prostate cancer. The approved product is a generic version of Zytiga tablets, 250 mg, of Janssen Biotech.
According to the company in its regulatory filing, “Glenmark Pharmaceuticals Inc., USA has been granted final approval by the United States Food & Drug Administration (USFDA) for Abiraterone Acetate tablets USP, 250 mg.”
As per the sales data by IQVIA for the 12-month period that ended in August 2019, Glenmark said that the Zytiga tablets, 250 mg market has achieved an annual sale of approximately US$ 794.1 million.
Currently, Glenmark’s portfolio has 162 products authorised for distribution in the US marketplace and 46 ANDA’s pending approval with the USFDA.
Source: IBEF
Image Courtesy: IndiaMart
You may also like
-
India Against Mpox
-
Combination of ‘Siddha’ Drugs Reduces Anemia in Adolescent Girls: Study
-
Suspected Mpox Case Under Investigation; Patient Put Under Isolation, No Cause for Alarm
-
Prime Minister Applauds India’s Best Ever Performance at the Paralympic Games
-
National Exit Test (NExT) for Ayush to be Effective from 2021-2022 Batch: Union Minister of Ayush Shri Prataprao Jadhav
